Summary
Since in patients with ventricular tachycardia (VT) and compromised left ventricular function, antiarrhythmic therapy poses a particular problem, an open-label safety study of d-sotalol, a new class III antiarrhythmic agent, was performed. Thirteen patients with defined VT and a low left ventricular ejection fraction (LVEF) were treated with orally administered d-sotalol, 100 mg bid, and in a few patients 100 mg tid, in an open study. Patients were followed up for 35±11 months, with the longest follow-up amounting to 51 months. The data obtained suggest that d-sotalol was moderately effective as an antiarrhythmic agent, in particular with respect to premature ventricular contractions (PVCs) and coupled and repetitive PVCs. The beneficial effect appeared to persist on long-term treatment. d-Sotalol was well tolerated and no subjective or objective adverse reactions were observed. There were no signs of worsening of congestive heart failure, proarrhythmogenic activity, or torsades de pointes, although QT-prolongation was observed. There were no dropouts in the study. Two patients died: One patient with idiopathic dilated cardiomyopathy (with LVEF=11%) died suddenly after 38 months of follow-up and one patient after 17 months from recurrent myocardial infarction. Neither of these had shown recurrence of VT on 24 hour ambulatory ECG recordings. In conclusion, in this small group of patients d-sotalol appeared to be safe and well tolerated during long-term treatment of patients with VT and poor left ventricular function. There were clear suggestions of antiarrhythmic activity, reflected by the suppression of complex ventricular arrhythmias and by the absence of recurrent VT on long-term follow-up in the majority of patients. These results would encourage a larger, formal trial on the use of d-sotalol in this type of patients,.
Similar content being viewed by others
References
Hammermeister KE. Adverse hemodynamic effects of antiarrhythmic drugs in congestive heart failure.Circulation 1990;81:1151–1153.
Singh BN. Amiodarone: Historical development and pharmacologic profile.Am Heart J 1983;106:788–797.
Singh BN, Nademanee K. Amiodarone and thyroid function: Clinical implications during antiarrhythmic therapy.Am Heart J 1983;106:857–859.
Singh BN, Nademanee K. Sotalol, a beta-blocker with unique antiarrhythmic properties.Am Heart J 1987;114:121–139.
Singh BN, Deedwania P, Nademanee K, Weud A, Sorkin EM. Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs 1987;34:311–349.
Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with sotalol in patients with drug-refractory ventricular arrhythmias.J Am Coll Cardiol 1989;13:145–152.
Petzl DH, Probst P, Glogar D, Schuster E. The effect of sotalol on exercise-induced ventricular arrhythmias.Eur Heart J 1988;9:265–270.
Ramsdale DR, Llewellyn MJ, Pidgeon J, Faragher EB, Charles RB. Effects of intravenous sotalol on the Q-T interval and incidence of ventricular arrhythmias early in acute myocardial infarction.Am J Noninv Cardiol 1988;2:52–58.
Hohnloser SH, Woosley RL. Sotalol.N Engl J Med 1994;331:31–38.
Brachmann J, Schöls W, Schmitt C, Waldecker B, Wöhrnschimmel E. Refractory sustained ventricular tachycardia: Role of d-sotalol.Circulation 1988;78:60.
Brachmann J, Beyer T, Schöls W, et al. Electrophysiologic and antiarrhythmic effects of d-sotalol.J Cardiovasc Pharmacol 1992;20(Suppl 2):S91-S95.
Echt DS, Liebson PR, Mitchel LB, et al. Mortality and morbidity in patients receiving encainide, flecainide or placebo: The Cardiac Arrhythmia Suppression Trial.N Engl J Med 1991;324:781–788.
Waagstein F, Bristow MR, Swedbey K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy.Lancet 1993;342:1441–1446.
Katritsis D, Camm AJ. New class III antiarrhythmic drugs.Eur Heart J 1993;14(Suppl H):93–99.
Aström M, Edhag O, Nyquist O, Vallin H. Electrophysiological effects of intravenous sotalol in acute myocardial infarction: A double-blind placebo-controlled study.Eur Heart J 1990;11:35–42.
Kopelman HA, Woosley L, Lee JT, Roden DM, Echt DS. Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease.Am J Cardiol 1988;61:1006–1011.
Jordaens LJ, Palmer A, Clement D. Low-dose oral sotalol for monomorphic ventricular tachycardia: Effects during programmed electrical stimulation and follow-up.Eur Heart J 1989;10:218–226.
Trappe HJ, Klein H, Lichtlen P. Sotolol in patients with life-threatening ventricular tachyarrhythmias.Cardiovas Drugs Ther 1990;4:1425–1432.
Amiodarone vs. Sotalol Study Group. Multicentre randomized trial of sotalol vs. amiodarone for chronic malignant ventricular tachyarrhythmias.Eur Heart J 1989;10:685–694.
Mason JW, for the ESVEM investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias.N Engl J Med 1993;329:452–458.
Tande PM, Refsum H. Class III antiarrhythmic action linked with positive inotropy: Effects of the d- and l-isomer of sotalol on isolated rate atria at threshold and supra threshold stimulation.Pharmacol Toxicol 1988;62:272–277.
Carmeliet E. Electrophysiologic and voltage clamp analysis of the effects of sotalol on isolated cardiac muscle and Purkinji fibers.J Pharmacol Exp Ther 1985;232:817–821.
Gomoll AW, Bartek MJ. Comparative β-blocking activities and electrophysiologic actions of racemic sotalol and its optical isomers in anesthetized dogs.Eur J Pharmacol 1986;132:123–135.
Kwan YW, Solca AM, Qwilt M, Kane A, Wadsworth RM. Comparative antifibrillatory effects of d- and dl-sotalol in normal and ischemic ventricular muscle of the cat.J Cardiovasc Pharmacol 1990;15:233–238.
Hoffmeister HM, Beyer M, Spiel L. Hemodynamic effects of d- and l-isomers of sotalol on normal myocardium.Cardiovasc Drugs Ther 1991;5:1027–1033.
Soyka LF, Wirtz C, Spangenberg ZRB. Clinical safety profile of sotalol in patients with arrhythmias.Am J Cardiol 1990;65(Suppl):74A-81A.
Cohn JM, Archibald DG, Francis GS. Veterans Administration Cooperative Study on vasodilator therapy of heart failure: Influence of prerandomisation variable on the reduction of mortality by treatment with hydralazine and isosorbide dinitrate.Circulation 1987;75(Suppl IV):IV-49.
Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic drug efficacy for ventricular tachyarrhythmias.N Engl J Med 1993;329:445–451.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Koch, K.T., Düren, D.R. & van Zwieten, P.A. Long-term antiarrhythmic efficacy and safety of d-sotalol in patients with ventricular tachycardia and a low ejection fraction. Cardiovasc Drug Ther 9, 437–443 (1995). https://doi.org/10.1007/BF00879033
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00879033